Hsbc Holdings PLC Decreases Stock Position in Cerus Co. (NASDAQ:CERS)

Hsbc Holdings PLC decreased its stake in shares of Cerus Co. (NASDAQ:CERS) by 12.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 118,158 shares of the biotechnology company’s stock after selling 17,410 shares during the quarter. Hsbc Holdings PLC’s holdings in Cerus were worth $203,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Cerus by 1.1% during the first quarter. Vanguard Group Inc. now owns 9,983,963 shares of the biotechnology company’s stock worth $18,870,000 after buying an additional 113,292 shares in the last quarter. Nikko Asset Management Americas Inc. grew its holdings in Cerus by 2.4% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 7,750,700 shares of the biotechnology company’s stock worth $14,571,000 after acquiring an additional 182,629 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its position in shares of Cerus by 2.4% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,750,700 shares of the biotechnology company’s stock valued at $14,649,000 after purchasing an additional 182,629 shares during the last quarter. Wasatch Advisors LP raised its holdings in shares of Cerus by 11.2% in the 4th quarter. Wasatch Advisors LP now owns 6,530,019 shares of the biotechnology company’s stock valued at $14,105,000 after purchasing an additional 656,971 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its holdings in shares of Cerus by 4.4% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 2,696,560 shares of the biotechnology company’s stock valued at $5,096,000 after purchasing an additional 114,628 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Insider Activity at Cerus

In other news, insider Richard J. Benjamin sold 21,605 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $2.50, for a total transaction of $54,012.50. Following the completion of the sale, the insider now owns 438,007 shares in the company, valued at approximately $1,095,017.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Richard J. Benjamin sold 21,605 shares of Cerus stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the sale, the insider now owns 438,007 shares in the company, valued at approximately $1,095,017.50. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Dennis Green sold 28,385 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the sale, the chief financial officer now directly owns 590,365 shares of the company’s stock, valued at approximately $1,286,995.70. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by corporate insiders.

Cerus Stock Performance

Shares of CERS stock opened at $1.70 on Friday. The company has a market cap of $314.31 million, a P/E ratio of -10.00 and a beta of 1.18. The firm has a fifty day moving average price of $2.07 and a 200 day moving average price of $1.93. The company has a current ratio of 2.51, a quick ratio of 1.83 and a debt-to-equity ratio of 1.29. Cerus Co. has a 12 month low of $1.21 and a 12 month high of $2.59.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.01. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. The business had revenue of $45.08 million during the quarter, compared to analysts’ expectations of $42.50 million. During the same period in the prior year, the firm posted ($0.07) EPS. Sell-side analysts predict that Cerus Co. will post -0.13 earnings per share for the current fiscal year.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.